...
首页> 外文期刊>Cancer Cell >TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RAR alpha and Inhibition of p53-Mediated Senescence
【24h】

TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RAR alpha and Inhibition of p53-Mediated Senescence

机译:TRED3通过稳定癌蛋白PML-RALα和抑制p53介导的衰老促进APL进展

获取原文
获取原文并翻译 | 示例
           

摘要

Acute promyelocytic leukemia (APL) is driven by the oncoprotein PML-RAR alpha, which antagonizes myeloid differentiation and promotes APL-initiating cell self-renewal. Combined all-trans retinoic acid (ATRA) with arsenic trioxide (As2O3) or chemotherapy dramatically improves the prognosis of APL patients. Here we report that expression of pseudokinase Tribble 3 (TRIB3) associates positively with APL progression and therapeutic resistance. The elevated TRIB3 expression promotes APL by interacting with PML-RAR alpha and suppressing its sumoylation, ubiquitylation, and degradation. This represses PML nuclear body assembly, p53-mediated senescence, and cell differentiation, and supports cellular self-renewal. Genetically inhibiting TRIB3 expression or combination of a peptide disturbing TRIB3/PML-RAR alpha interaction with ATRA/As2O3 eradicates APL by accelerating PML-RAR alpha degradation. Our study provides insight into APL pathogenesis and a potential therapeutic option against APL.
机译:急性高幼粒细胞白血病(APL)由癌蛋白PML-RARα驱动,其拮抗髓样分化并促进APL引发细胞自我更新。 结合所有二氧化砷(As2O3)或化疗的全反式视黄酸(ATRA)显着提高了APL患者的预后。 在这里,我们认为伪胰蛋白酶的表达Tribble 3(TRIB3)与APL进展和治疗抵抗力相关联。 通过与PML-RALα相互作用并抑制其平等,泛醌,降解,升高的THE表达促进APL促进APL。 这镇压PML核体组件,P53介导的衰老和细胞分化,并支持细胞自我更新。 遗传抑制肽的表达或肽的表达或组合干扰TRAd3 / PML-RARα与ATRA / As2O3的相互作用通过加速PML-RARα降解来消除APL。 我们的研究提供了对APL发病机制的洞察力和对APL的潜在治疗选择。

著录项

  • 来源
    《Cancer Cell》 |2017年第5期|共21页
  • 作者单位

    Chinese Acad Med Sci Inst Med Biotechnol Beijing 100050 Peoples R China;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Hematol Hematopoiet Stem Cell Transplantat Ctr Tianjin 300020 Peoples;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Hematol Hematopoiet Stem Cell Transplantat Ctr Tianjin 300020 Peoples;

    Chinese Acad Med Sci Inst Basic Med Beijing 100005 Peoples R China;

    Shandong Univ Marine Coll Dept Pharm Weihai 264209 Peoples R China;

    Shandong Univ Marine Coll Dept Pharm Weihai 264209 Peoples R China;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

    Chinese Acad Med Sci Inst Mat Med State Key Lab Bioact Subst &

    Funct Nat Med Immunol &

    Canc;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号